Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Simon Zhou"'
Autor:
Jamie N. Connarn, Han Witjes, Marielle van Zutphen‐van Geffen, Rik deGreef, Timothy B. Campbell, Kristen Hege, Simon Zhou, Manisha Lamba
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 11, Pp 1687-1697 (2023)
Abstract Idecabtagene vicleucel (ide‐cel; bb2121) is a B‐cell maturation antigen–directed chimeric antigen receptor (CAR) T cell therapy approved for treatment of patients with heavily pretreated relapsed and refractory multiple myeloma. This a
Externí odkaz:
https://doaj.org/article/cedc81b5533d4fda88aaa6bfdc554148
Publikováno v:
eJHaem, Vol 3, Iss 3, Pp 815-827 (2022)
Abstract Early prognosis of clinical efficacy is an urgent need for oncology drug development. Herein, we systemically examined the quantitative approach of tumor growth inhibition (TGI) and survival modeling in the space of relapsed and refractory m
Externí odkaz:
https://doaj.org/article/f724d2c040e14237bef0378fc971f6a4
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 7, Pp 3049-3062 (2022)
Ninety percent of clinical drug development fails despite implementation of many successful strategies, which raised the question whether certain aspects in target validation and drug optimization are overlooked? Current drug optimization overly emph
Externí odkaz:
https://doaj.org/article/c83f55dcfaec4f418216ac4875b7cd5d
Autor:
Wei Gao, Hongxiang Hu, Lipeng Dai, Miao He, Hebao Yuan, Huixia Zhang, Jinhui Liao, Bo Wen, Yan Li, Maria Palmisano, Mohamed Dit Mady Traore, Simon Zhou, Duxin Sun
Publikováno v:
Acta Pharmaceutica Sinica B, Vol 12, Iss 5, Pp 2462-2478 (2022)
Drug optimization, which improves drug potency/specificity by structure‒activity relationship (SAR) and drug-like properties, is rigorously performed to select drug candidates for clinical trials. However, the current drug optimization may overlook
Externí odkaz:
https://doaj.org/article/8f3478b4480b4cadbce522dd147c6570
Autor:
Nianhang Chen, Nastya Kassir, Abderrahmane Laadem, Stephen E. Maxwell, Priya Sriraman, Ana Carolina Giuseppi, Steve Ritland, Peter G. Linde, Balasubrahmanyam Budda, Joseph G. Reynolds, Simon Zhou, Maria Palmisano
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 9, Iss 7, Pp 395-404 (2020)
Luspatercept is a recombinant fusion protein that enhances late‐stage erythroid maturation. This report describes the population pharmacokinetics and exposure–response relationship of luspatercept in 260 patients with anemia due to myelodysplasti
Externí odkaz:
https://doaj.org/article/b71c1d3971b14218bd2a4fcb5ebcb47a
Publikováno v:
Oncology and Therapy, Vol 8, Iss 1, Pp 91-102 (2019)
Abstract Introduction The purpose of this study was to evaluate the absolute bioavailability (BA) of AG-221 following a single oral dose of 100 mg AG-221 and an intravenous (IV) dose of ~ 100 μg AG-221 containing approximately 300 nCi of [14C]-AG-22
Externí odkaz:
https://doaj.org/article/d50ee59b08634cfea1ec1d57983793cf
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0249117 (2021)
Macrophages and dendritic cells (DCs) are innate immune cells that play a key role in defense against pathogens. In vitro cultures of bone marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs) are well-established and valuable methods for im
Externí odkaz:
https://doaj.org/article/22da9b9bd0a2454bbf370e013304dc08
Autor:
Simon Zhou, Xuesong, Cheng, Qixiu, Wu, Xin, Li, Peiheng, Belezamo, Baloka, Lu, Jiawei, Abbasi, Mohammad
Publikováno v:
In Multimodal Transportation June 2022 1(2)
Autor:
Yiming Cheng, Ying Ye, Allison Gaudy, Atalanta Ghosh, Yongjun Xue, Alice Wang, Simon Zhou, Yan Li
Publikováno v:
Clinical Pharmacology: Advances and Applications. 15:9-19
Yiming Cheng,1 Ying Ye,1 Allison Gaudy,1 Atalanta Ghosh,2 Yongjun Xue,3 Alice Wang,1 Simon Zhou,1 Yan Li1 1Clinical Pharmacology & Pharmacometrics, Bristol Myers Squibb, Princeton, NJ, USA; 2Global Biometrics and Data Sciences, Bristol Myers Squibb,
Publikováno v:
Transportation Research Part B: Methodological. 166:143-182